

ISSN 1097-4644 (Print) / ISSN 1097-4652 (Online)



Taylor &
Francis
Publishing

Food and Nutrition Sciences



www.tandf.co.uk/journals



Submission

Food and Nutrition Sciences

ISSN Print: 2157-944X

ISSN Online: 2157-9458

www.scirp.org/journal/fns

E-mail: fns@scirp.org

Citations [h5-index & Ranking](#)

Editor-in-Chief

Prof. **Alessandra Bordoni**, University of Bologna, Italy

Associate Editors-in-Chief

Prof. **Xufeng Huang**, University of Wollongong, Australia

Prof. **Michael G. Kontominas**, University of Ioannina, Greece

Editorial Board

Prof. **Hülya Çiçek**, Gaziantep University, Türkiye

Dr. **Ammar Mohammed Hamood AL-Farga**, University of Jeddah, Saudi Arabia

Dr. **Kayanush J. Aryana**, Louisiana State University, USA

Dr. **Lauri O. Byerley**, Louisiana State University, USA

Dr. **Daniel Cozzolino**, The University of Adelaide, Australia

Dr. **Amira Muhammad Galal Darwish**, City of Scientific Research and Technological Applications (SRTA City), Egypt

Prof. **Kelvin J. A. Davies**, University of Southern California, USA

Dr. **Amith R. Devireddy**, University of Missouri, USA

Prof. **Asim K. Duttaroy**, University of Oslo, Norway

Prof. **Yousif Abd El-Aziz Abdou Elhassaneen**, Minoufiya University, Egypt

Dr. **Anthony Fardet**, Institute National de la Recherche Agronomique (INRA),
France

Prof. **Tomas Girbes**, University of Valladolid, Spain

Dr. **Beau K. Greer**, Sacred Heart University, USA

Dr. **Jeffrey S. Hampl**, Arizona State University, USA

Prof. **Yong He**, Zhejiang University, China

Dr. **Kimberly B. Heidal**, East Carolina University, USA

Prof. **Yu Huang**, Chinese University of Hong Kong, China

Dr. **Jose C. Jimenez-Lopez**, Spanish National Research Council (CSIC), Spain

Dr. **Jagat R. Kanwar**, Deakin University, Australia

Dr. **Dalia El Khoury**, University of Guelph, Canada

Prof. **Patricia A. Kruk**, University of South Florida, USA

Dr. **Jean-Claude Lavoie**, University of Montreal, Canada

Dr. **Francisco Sánchez Montero**, College of Nutrition Professionals of Costa
Rica, Costa Rica

Dr. **Francisco Javier Moreno**, Autonomous University of Madrid, Spain

Prof. **Hasan Mukhtar**, University of Wisconsin, USA

Dr. **Maurice O'Sullivan**, University College Cork, Ireland

Dr. **Mustafa Zafer Ozel**, The University of York, UK

Dr. **Uma Devi Palanisamy**, Monash University, Sunway Campus, Australia

Prof. **Young W. Park**, Fort Valley State University, USA

Dr. **Salina Parveen**, University of Maryland Eastern Shore, USA

Dr. **Reza Poureslami**, Insta-Pro International, USA

Dr. **Jayadev Raju**, Health Canada, Canada

Prof. **Sherif Sabry**, Menoufia University, Egypt

Prof. **Charles R. Santerre**, Purdue University, USA

Dr. **Heidi J. Silver**, Vanderbilt University, USA

Prof. **Jesus Simal-Gandara**, University of Vigo, Spain

Prof. **Linda G. Snetselaar**, The University of Iowa, USA

- Dr. **Lucy Thairu**, Touro University, USA
- Dr. **Brijesh Kumar Tiwari**, Manchester Metropolitan University, UK
- Prof. **Alan C. Tsai**, Asia University, Chinese Taipei
- Prof. **Edwin Edward Kadima Wamukoya**, Masinde Muliro University of
Science and Technology, Kenya
- Dr. **Thomas T. Y. Wang**, Johns Hopkins University, USA
- Dr. **Jack Wing Tak Wong**, Stanford University, USA
- Prof. **Baojun Xu**, Beijing Normal University-Hong Kong Baptist University United
International College, China



[Submission](#)

Food and Nutrition Sciences

ISSN Print: 2157-944X

ISSN Online: 2157-9458

www.scirp.org/journal/fns

E-mail: fns@scirp.org

[Citations](#) [h5-index & Ranking](#)

Indexing

Web of Science (Clarivate Analytics)

There are 10352 citations for articles published in the journal FNS as of June 2022, which

increase by 13% compared to 9192 citations as of June 2021.

Please click the following link to see the [screenshot](#).

Google Scholar

There are [30177 citations](#) for articles published in the journal FNS as of July 2022 based on the statistics from Google Scholar.

The 2-year Google-based Journal Impact Factor (2-GJIF) is 0.92.

CABI Database

FNS is indexed by CABI, which is one of the 9 databases in the "Web of Science".

Please check the [screenshot](#).

PubMed and PubMed Central

Some FNS papers have been indexed by [PubMed](#) and [PubMed Central](#).

FNS has been indexed by several world class databases. For more information, please access the following links:

- [Academic Journals Database](#)
- [AiritiLibrary](#)
- [CABI Database](#)
- [CALIS](#)
- [ChaoXing Periodicals](#)
- [Chemical Abstracts Service \(CAS\)](#)
- [CNKI Scholar](#)
- [Cnplinker](#)
- [COPAC](#)
- [CQVIP](#)
- [CrossRef](#)

- **Elektronische Zeitschriftenbibliothek (EZB)**
- **ERA 2018 Journal List**
- **European Virtual Institute for Speciation Analysis (EVISA)**
- **Geneva Foundation for Medical Education and Research (GFMER)**
- **GETIT@YALE(Yale University Library)**
- **Harvard Library E-Journals**
- **Infotrieve**
- **i-Scholar**
- **JournalSeek**
- **JournalTOCs**
- **National Center for Philosophy and Social Sciences Documentation**
- **National Science and Technology Library(NSTL)**
- **National Science Library, Chinese Academy of Sciences (NSLC)**
- **Open Access Journals Search Engine (OAJSE)**
- **Open Access Library**
- **Open J-Gate**
- **PUBDB DESY Publication Database**
- **PubScholar**
- **QUALIS/CAPEs**
- **ResearchGate**
- **SciFinder**
- **SciLit**
- **SHERPA/RoMEO**
- **Stanford University Libraries**
- **Technische Informationsbibliothek (TIB)**
- **The Library of Congress**
- **WanFang**
- **Worldcat**
- **Zeitschriftendatenbank (ZDB)**



Submission

Food and Nutrition Sciences

ISSN Print: 2157-944X

ISSN Online: 2157-9458

www.scirp.org/journal/fns

E-mail: fns@scirp.org

[Citations](#) [h5-index & Ranking](#)

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2023 >>

1110987654321

Volume 14, Number 10, October 2023

Cover Page, Table of Contents and Others: PDF (size: 8625KB)

- **Safety Evaluations of Long-Term and Excessive Intakes of *Bifidobacterium longum* CLA8013: A Placebo-Controlled, Randomized, Double-Blind Study**

Daisuke Takami, Keisuke Okada, Yutaka Makizaki, Yoshiki Tanaka, Hiroshi Ohno, Daisuke Tsuge

Food and Nutrition Sciences Vol.14 No.10, October 31, 2023

DOI: [10.4236/fns.2023.1410063](https://doi.org/10.4236/fns.2023.1410063) 22 Downloads 100 Views

-
- **Factors Related to the Reading Nutritional Labels by Consumers**
-

Ellen Rodrigues dos Santos, José Eduardo Corrente, Rachel Santos Bueno
Carvalho, Giovana Fumes-Ghantous

Food and Nutrition Sciences Vol.14 No.10, October 31, 2023

DOI: 10.4236/fns.2023.1410062 11 Downloads 79 Views

- **β -Glucans: Characterization, Extraction Methods, and Valorization**
-

Ana Chioru, Aurica Chirsanova

Food and Nutrition Sciences Vol.14 No.10, October 31, 2023

DOI: 10.4236/fns.2023.1410061 26 Downloads 236 Views

- **Glycemic Indices of Multiple Oral Nutritional Supplements: A Randomized Cross-Over Study in Indian Adults**
-

Deepti Khanna, Jaladhi Bhatt, Jayanti Gupta, Simran Sethi, Parth Joshi, Manoj
Pareek, Divya Agrawal

Food and Nutrition Sciences Vol.14 No.10, October 31, 2023

DOI: 10.4236/fns.2023.1410060 19 Downloads 305 Views

- **Dietary Vitamin K Restriction and Effectiveness of Vitamin K Antagonists Prescribed at the CNHU-HKM University Cardiology Clinic/BENIN**
-

Clémence Germaine Metonnou, Charles Jérôme Sossa, Lamidhi

Salami, Rébecca Sabgohan, Colette Azandjeme, Camelle Mizehoun-

Adossoda, Virginie Mongbo

Food and Nutrition Sciences Vol.14 No.10, October 30, 2023

DOI: 10.4236/fns.2023.1410059 10 Downloads 56 Views

- **Prevalence and Predictors of Double Burden of Malnutrition within Households in Africa: A Systematic Review**
-

Reynald Santos, Charles Sossa Jerome, Colette Azandjeme, Carmelle

Mizehoun-Adissoda, Clémence Metonnou

Food and Nutrition Sciences Vol.14 No.10, October 30, 2023

DOI: 10.4236/fns.2023.1410058 18 Downloads 61 Views

- **Assessment of the Aflatoxin Content of Maize Flours Produced in the Commune of Ouagadougou, Burkina Faso**
-

[Adama Sawadogo, Raoul Bazié, Hama Cissé, Latifatou Helbi, Cheikna Zongo, Aly Savadogo](#)

Food and Nutrition Sciences Vol.14 No.10, October 23, 2023

DOI: [10.4236/fns.2023.1410057](https://doi.org/10.4236/fns.2023.1410057) 24 Downloads 126 Views

- **Prescription and Delivery of Enteral Nutrition for ICU Patients: A Case Study of a Hospital in the Interior of Brazil**
-

[Valtemir Paula de Oliveira Junior, Daiane Costa dos Santos, Sibeles Santos Fernandes, Mariana Buranelo Egea](#)

Food and Nutrition Sciences Vol.14 No.10, October 23, 2023

DOI: [10.4236/fns.2023.1410056](https://doi.org/10.4236/fns.2023.1410056) 17 Downloads 97 Views

Dietary Vitamin K Restriction and Effectiveness of Vitamin K Antagonists Prescribed at the CNHU-HKM University Cardiology Clinic/BENIN

Clémence Germaine Metonnou^{1*}, Charles Jérôme Sossa¹, Lamidhi Salami², Rébecca Sabgohan³, Colette Azandjeme¹, Camelle Mizehoun-Adossoda³, Virginie Mongbo²

¹Health Promotion Department, Regional Institute of Public Health, University of Abomey-Calavi, Ouidah, Benin

²Health Policy and Systems Department, Regional Institute of Public Health, University of Abomey-Calavi, Abomey-Calavi, Benin

³School of Nutrition-Dietetics, Faculty of Health Sciences, University of Abomey-Calavi, Cotonou, Benin

Email: *metonnouc@yahoo.fr

How to cite this paper: Metonnou, C.G., Sossa, C.J., Salami, L., Sabgohan, R., Azandjeme, C., Mizehoun-Adossoda, C. and Mongbo, V. (2023) Dietary Vitamin K Restriction and Effectiveness of Vitamin K Antagonists Prescribed at the CNHU-HKM University Cardiology Clinic/BENIN. *Food and Nutrition Sciences*, 14, 928-940.
<https://doi.org/10.4236/fns.2023.1410059>

Received: August 26, 2023

Accepted: October 27, 2023

Published: October 30, 2023

Copyright © 2023 by author(s) and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).

<http://creativecommons.org/licenses/by/4.0/>



Open Access

Abstract

Introduction: Their efficacy in preventing thrombotic and embolic events has been proven in numerous studies, but their narrow therapeutic index requires particular vigilance, especially in terms of biology. In addition, treatment-related hemorrhagic complications are not uncommon. This study explores the influence of dietary vitamin K restriction on the efficacy of anti-vitamin K treatment at the University Cardiology Clinic of CNHU-HKM. **Methods:** Cross-sectional and descriptive study that took place from 25 April to 29 August 2019. Patients' dietary behaviors and successive INR values were collected. Information on dietary intake was obtained by 2 non-consecutive 24-hour recalls. The effectiveness of VKA treatment was assessed by the "Time in Therapeutic Range" (TTR) of the INR. VKA treatment was considered effective for a TTR greater than 65%. **Results:** At the end of this study, 40 patients were surveyed. The mean age of the participants was 58.05 years \pm 13.32 years, with a sex ratio of 1.35. Complete arrhythmia due to atrial fibrillation was the main indication for VKA treatment (37.50%) and fluindione was the most commonly prescribed drug (77.50%). The duration of treatment was less than or equal to 2 years in 47.5% of the subjects surveyed. Before starting treatment, 85% of patients received advice on restricting vitamin K-rich foods, and 45% of patients reported "food burnout" after a period of compliance with the restriction. The majority of respondents (97.50%) complied with the restriction on vitamin K-rich foods. All respondents had high energy intakes and a poor distribution of macronutrients, with a predominance of carbohydrates and proteins. 2.5% of respondents were on effective anti-vitamin K therapy with a TTR of over 65%. **Conclusion:** Restriction of

vitamin K-rich foods is not conducive to effective treatment with vitamin K antagonists.

Keywords

Antivitamin K, Dietary Restriction, Vitamin K, Therapeutic Efficacy

1. Introduction

Atherosclerotic cardiovascular disease remains one of the leading causes of death worldwide, despite the availability of risk-modifying treatments and lifestyle advice [1]. Antivitamins K (AVKs) belong to the family of oral anticoagulants, widely prescribed in the management of a number of cardiovascular diseases. Patients prescribed these VKAs risk being under-dosed, with inadequate protection against thromboembolism, or over-dosed, with a high risk of hemorrhage [2]. Studies by Rombouts et al. have shown an interaction between vitamin K intake and oral anticoagulation therapy [3]. Patients treated with VKAs are often advised to restrict their vitamin K intake, but recent data in the literature tend to show the benefits of a balanced diet, with unrestricted consumption of foods containing vitamin K [4]. Anticoagulation Dietary vitamin K intake restriction event thromboembolic events in a number of situations: mechanical heart valve replacement (MHRV), atrial fibrillation (AF), deep thrombophlebitis, and/or pulmonary embolism [5]. The frequency and seriousness of bleeding on anticoagulants make them a dreaded event, and their management must be well codified. Vitamin K, by allowing endogenous hepatic production of factors five to six hours after administration, takes over from the exogenous factors supplied and ensures that correct hemostasis is maintained from the sixth hour until the disappearance of circulating VKA molecules. Rapid antagonization of VKA treatment requires the administration of clotting factor concentrates (commonly known as prothrombin, proconvertin, Stuart factor, anti-hemophilic factor B [AHFB]) and vitamin K. PPSB is the antidote to VKAs. This combination is recommended by Anglo-Saxon learned societies and by Afssaps [6] [7] [8] [9]. The administration of vitamin K is essential in view of the pharmacological properties of coagulation factors. The short half-life (five to six hours) of factor VII limits the duration of action of PPSB [10] [11]. Dietary vitamin K intake restriction was still recommended for patients treated with VKAs at the University Cardiology Clinic of the CNHU HKM in Cotonou. This study examines the influence of dietary vitamin K restriction on the efficacy of VKA treatment at the University Cardiology Clinic of the CNHU HKM in Cotonou (BENIN).

2. Study Methods

2.1. Type of Study

This was a cross-sectional, descriptive, and analytical study.

2.2. Study Population

This study focused on patients treated with VKAs in the cardiology department of the CNHU HKM who were admitted to the heart failure treatment unit during the data collection period.

2.3. Inclusion Criteria

Patients treated with VKAs at the CNHU, who had given informed consent and who had a VKA monitoring record, were included in the study.

2.4. Criteria for Non-Inclusion

Patients with a medical condition that prevented them from completing the questionnaire and those represented by their close relatives or parents during the monitoring of VKA treatment were not included in the study.

2.5. Exclusion Criteria

Patients who had less than three International normalized ratios and less than two 24-hour recalls during data collection were excluded from the study.

2.6. Sampling

Patients were selected by the non-probability method using a convenience sampling technique.

2.7. Variables and Their Measurements

The variables described were sociodemographic characteristics: age, sex, profession; level of education; nutritional status of patients, which was assessed on the basis of body mass index (BMI) defined according to WHO criteria; indication for treatment; type of anti-vitamin K (AVK); duration of AVK treatment; patient behavior, which was assessed using eight items: dietary “burn out”, weight loss diet, degree of motivation to comply with restrictions, compliance with vitamin K restriction recommended by the doctor, use of herbal teas, compliance with appointment dates, compliance with vitamin K restriction.

Socio-demographic data were collected using a questionnaire.

Age has been classified into three categories: 30 - 45 years; 45 - 60 years and 60 - 85 years. The profession has taken into account: householders, shopkeepers and farmers, civil servants, pensioners, and craftsmen. The level of education was indicated by: no level, literate, primary level, secondary level, and university level.

Anthropometric measurements (height and weight) were taken using SECA adult height gauges and scales respectively. For weight, subjects were placed on a scale without shoes and in light clothing in a stand. To take account of any overestimation of weight due to the fact that the individuals had not completely undressed at the time of weighing, the investigators applied a systematic weighting of 250 grams to all the individuals before recording the corrected weights on the survey form. For height, the Olivier and Demoulin protocol was used as a guide

[2]. Nutritional status was assessed by calculating the Body Mass Index (BMI). This was used to classify subjects in accordance with WHO criteria (BMI ≥ 30 kg/m²: obese, BMI 25 - 29.99 kg/m²: overweight, BMI 18.5 - 24.99 kg/m²: normal weight and BMI < 18.5 kg/m²: underweight) [2].

The indication for anti-vitamin K treatment was assessed on the basis of the pathologies present in the patients. These were deep vein thrombosis, pulmonary embolism, mechanical valve prosthesis, complete arrhythmia due to atrial fibrillation, spontaneous intracardiac contrast, chronic pulmonary heart disease due to pulmonary arterial hypertension, and mitral stenosis.

The type of anti-vitamin K was assessed through the type of anti-vitamin K prescribed to patients. Three molecules were found: fluindione, acenocoumarol, and warfarin.

The duration of treatment took into account the start of antivitamin K treatment up to the date of data collection. It was categorized into several time intervals: less than six months, one to two years, two to three years, three to five years, five to ten years, and 15 to 18 years.

The patient's behavior was assessed using a six-item questionnaire: dietary "burnout". We considered that a patient was a victim of dietary "burnout" when, after trying to comply with the dietary restriction for a given period, he broke down and consumed a large quantity of food rich in vitamin K; the weight-loss diet considered patients who spontaneously reduced their food intake after the doctor's intervention; the degree of motivation to comply with the restrictions was evaluated by the same questionnaire with questions on: not at all motivated, a little motivated, acceptable, fairly motivated or very motivated; the patients' perception of the vitamin K restriction recommended by the doctor was assessed by the questionnaire with the items: very good, fairly good and nil; the use of herbal teas was assessed by whether or not traditional medicine was used; whether or not appointments were kept was assessed by the questionnaire.

Daily intakes of energy, macronutrients, vitamin K, and alcohol were estimated by two non-consecutive 24-hour recalls. These recalls enabled us to collect all the necessary information on the foods and quantities consumed in the week prior to their arrival at the hospital. We then used the Ciqual 2017 table and Excel software to calculate each patient's daily vitamin K intake. The recommended daily intake of vitamin K1 is 60 to 100 micrograms per day. We decided that daily vitamin K1 intakes of less than 60 micrograms were considered insufficient and corresponded to compliance with dietary restrictions.

Compliance with vitamin K restriction is a quantitative variable transformed into a dichotomous categorical variable with two modes: "yes" and "no". The "yes" category corresponded to compliance with vitamin K restriction when intake was less than 60 micrograms; the "no" category corresponded to normal (60 - 100 micrograms) or high vitamin K intake. Finally, we assessed the effectiveness of the treatment, which was documented using a questionnaire. The efficacy of anti-vitamin K treatment was assessed by the Time in Therapeutic Range

(TTR) of three successive International Normalised Ratio (INR) values for patients during the study period. VKA treatment was considered effective for a TTR greater than 65%.

3. Data Analysis

The data were analyzed using IBM SPSS Software Statistics. 20. Means and percentages were calculated for quantitative and qualitative variables respectively. Nutrient intakes were estimated using the West African food composition table. In particular, the Ciqual 2017 table was used to estimate vitamin K intakes.

4. Results

4.1. Socio-Economic Status and Nutritional Status of Patients

At the end of this study, 50 patients were surveyed who met the inclusion criteria for this study. Ten patients who were unable to complete 3 INRs and 2 24-hour reminders during data collection were excluded from the study. The final sample size was 40 patients. The study showed that the mean age of the subjects was 58.05 years \pm 13.32 years, with extremes of 32 and 83 years. The predominant age group was 60 and over. The majority of patients were male (57.50%). The sex ratio was 1.35. In addition, most of the patients surveyed were civil servants (32.50%), and the majority had secondary education (42.50%) and university education (30%). Married people accounted for 75% of those surveyed. 55% of them were obese (**Table 1**).

Table 1. Distribution of patients according to their socioeconomic status and nutritional status (n = 40) [CNHU-HKM, Cotonou, Benin, 2019].

Variables	Eff.	%
Age (years)		
30 - 45	9	22.5
46 - 60	9	22.5
61 - 85	22	55.00
Gender		
Male	23	57.50
Female	17	42.50
Professions		
Artisans	3	7.50
Household	6	15.00
Shopkeepers / Farmers	8	20.00
Civil servants	13	32.50
Retirees	10	25.00
Level of education		
None	1	2.50

Continued

Literate	1	2.50
Primary	9	22.50
Secondary	17	42.50
University	12	30.00
Marital status		
Married	30	75.00
Common-law/ divorced	10	25.00
BMI*		
<18.5 underweight]	0	00.00
[18.5 - 24.99 normal weight]	2	5.00
[25 - 29.99 overweight]	16	40.00
[≥30 Obesity]	22	55.00

Body mass index.

Table 2. Breakdown of patients by indication for Antivitamin K treatment according to duration of treatment and type of treatment.

Variables	Indication for treatment of patients							%
	Deep vein thrombosis	Embolie pulmonary	Mechanical valve prosthesis	Complete atrial fibrillation arrhythmia	Spontaneous Intracardiac contrast	CPC* in primary PAH	RM*** percutaneous route complicated by ACFA	
Duration								
<6 mouths	-	2	-	3	-	-	-	12.5
6 months to 2 years	4	2	2	8	1	1	1	47.5
2 à 5 years	5	2	2	4	1	-	-	35.0
5 à 10 years	1	1	-	-	-	-	-	5.0
Type of treatment								
Fluindione	9	7	3	11	1	-	-	77.5
Acenocoumarol	1	-	1	4	-	1	1	20.0
Warfarin	-	-	-	-	-	-	1	2.5
%	25.00	17.50	10.00	37.50	5.00	2.50	2.50	100

*Chronic pulmonary heart disease; **Pulmonary arterial hypertension; ***Mitral stenosis.

4.2. Indications for Treatment with Antivitamin K Depending on the Duration and Type of Treatment

Table 2 shows the distribution of patients according to the indication for Antivitamin K treatment, the duration of treatment, and the type of treatment. The

table shows that the most frequent indication was complete arrhythmia due to atrial fibrillation (37.50%). It can also be seen that the percentage of patients decreases with the duration of treatment (19/40 patients between 6 months and 2 years of treatment fell to 2/40 patients between 5 and 10 years of treatment). Moreover, fluindione is the type of treatment most frequently applied to patients (31/40).

4.3. Patient Behavior (Table 3)

Table 3. Patient Behavior.

Variables	Eff.	%
Burn Out		
No	18	45.00
Yes	22	55.00
Beneficiaries of nutritional advice		
No	34	85.00
Yes	6	15.00
Weight loss diet		
No	30	75.00
Yes	10	25.00
Degree of motivation		
Not motivated	13	32.50
Quite motivated	8	20.00
Motivated	19	47.50
Patients' perception of carers' recommendations		
None	4	10.00
Fairly good	8	20.00
Very good	28	70.00
Keeping appointments		
No	29	72.50
Yes	11	27.50
Traditional treatment (herbal tea)		
No	16	40.00
Yes	24	60.00
Alcohol consumption		
No	21	52.50
Yes	19	47.50
Daily vitamin K intake		
Intake less than 60 mg	29	72.50

Continued

Intake greater than 60 mg	11	27.50
Treatment efficacy (TTR value)		
No (TTR < 65%)	28	70.00
Yes (TTR > 65%)	12	30.00
Macronutrient intake		
Carbohydrates		
High intakes	29	72.50
Low inputs	11	27.50
Proteins		
High intakes	30	75.00
Low inputs	10	25.00
Lipides		
High intakes	11	27.50
Low inputs	29	72.50

5. Discussion

The present study explored the influence of dietary vitamin K restriction on the efficacy of VKA treatment at the University Cardiology Clinic of the CNHU-HKM. The results show that the dietary behavior of patients at the University Cardiology Clinic of the CNHU-HKM influences the efficacy of treatment with vitamin K antagonists.

A high proportion (82.50%) of participants in this study reported having been advised to restrict their consumption of vitamin K-rich foods, mainly green vegetables. However, this proportion is higher than that reported in other studies of anti-coagulation patients taking VKAs. For example, in a study of Quebec patients taking Warfarin for anticoagulation, 68% reported having been advised to restrict their intake of foods rich in vitamin K, mainly green vegetables [1]. In another study of 185 American anti-clotting Warfarin patients, 32% said they should avoid spinach altogether when asked specifically about eating this vegetable [2]. A similar proportion of German patients thought they should avoid eating green vegetables and fruit during their VKA treatment [3]. Furthermore, in a study conducted in the UK, 16% of 114 patients reported having reduced their consumption of green vegetables following the initiation of Warfarin therapy [12]. All this evidence from scientific studies would have guided the carers in the CNHU cardiology department in advising patients taking VKAs to restrict vitamin K-rich foods. Of the patients who received advice about restricting vitamin K-rich foods, 14.71% were very motivated to follow the diet and 41.18% thought that the beneficial impact of the restriction on treatment was not good enough. In addition, 26.47% said they found it very difficult to follow the advice given. These data show that for these patients the restriction of vitamin K-rich

foods is very restrictive since most of the prohibited foods are part of their eating habits in Benin. The patients hardly consume any sauces, as they are forbidden vegetables in general and tomatoes and leafy vegetables in particular. Their diet is therefore reduced to starchy foods as a staple, followed by chili and onion as sauces, accompanied by a source of protein. As a result, patients are unable to enjoy all the pleasures of food, which could expose them to double stress, since they have to remember and take their VKA every day, preferably at the same time; and monitor the effectiveness of the treatment through regular blood tests, which require them to go to hospital to have their blood sample taken every time, not forgetting all the expenses associated with these requirements; and now think about what to eat to get pleasure without breaking the restrictions prescribed by the doctors.

Furthermore, restricting dietary vitamin K intake affects quality of life and was difficult to comply with, as shown by Leblanc C., in his study on the influence of dietary vitamin K intake on the efficacy of warfarin anticoagulation therapy. In this study, more than half of the participants who reported having received this recommendation indicated that they did not adhere to it, or adhered to it with difficulty, mainly because it went against their dietary habits or preferences [1].

With regard to patients' dietary behavior, 58.82% of patients suffered from "dietary burnout" after a period of compliance with dietary restrictions. Dietary burnout is the consequence of the difficulty of complying with the vitamin K dietary restriction, leading to a breakdown in compliance with the restriction. Two studies have shown that patients with low vitamin K status are also more sensitive to episodic consumption of vitamin K-rich foods, which may increase their risk of sub-therapeutic INR [13] [14].

This study reveals inappropriate dietary behavior in patients undergoing VKA treatment. Indeed, 40% of patients were fasting, 7.5% were on weight-loss diets, 16% were anorexic, 47.50% drank alcohol and 32.50% drank herbal teas. These data show that the nutritional advice given to patients prior to initiation of VKA treatment did not take into account inappropriate dietary behavior and focused almost exclusively on vitamin K restriction. This may be explained by the fact that there is no adequate nutritional management, administered to patients by a nutrition professional. In the present study, the mean vitamin K intake of patients was 28.14 ± 12.56 $\mu\text{g}/\text{day}$. This intake is lower than intakes calculated by other authors. Li *et al.* reported a median dietary vitamin K intake of 55 $\mu\text{g}/\text{day}$ in 282 Americans starting warfarin therapy, as assessed by a food diary [15]. The geometric mean dietary vitamin K intake was 107 $\mu\text{g}/\text{day}$ in 147 elderly Quebecers treated with warfarin, as assessed by a food frequency questionnaire [16]. The dissimilarity observed with the geometric mean obtained in this sample could result from a different proportion of patients adhering to a recommendation to restrict consumption of vitamin K-rich foods. It could also result from a difference between the dietary data collection tools used in the two studies and

this one. The majority of participants in this study (97.50%) complied with the restriction on vitamin K-rich foods. This result may be explained by the fact that patients invest many of their resources in treatment, which obliges them to comply with doctors' advice since they expect their health to improve. The mean TTR of participants in the present study was $37.39\% \pm 11.78\%$. These data were lower than those observed in American patients on VKA (55%) [17] and Quebec patients on VKA (72%) [1]. 2.5% of the participants in this study had effective treatment despite virtual compliance with restrictions on foods rich in vitamin K. Some studies have established that vitamin K can cause variations in INR, whether it is provided in the diet or in the form of a supplement: Scone E, in his case study (n = 26 in each group) comparing vitamin K consumption in stable and unstable patients reported that vitamin K consumption was much lower in unstable patients ($p < 0.001$) [18]. Schurgers *et al.*, in a dose-response study of 12 healthy volunteers stabilized on acenocoumarol, demonstrated that the threshold dose of vitamin K1 when supplemented resulted in a significant reduction in INR of 150 $\mu\text{g}/\text{d}$ ($p < 0.05$), with a test of the effect of different foods showing that a single meal including food rich in vitamin K did not result in a clinically significant variation in INR [19]. The possibility of vitamin K supplementation in patients with unstable oral anticoagulant therapy has been evaluated in several studies: Scone showed that the intake of 150 $\mu\text{g}/\text{d}$ of vitamin K for 6 months reduced the variability of INR ($p < 0.001$) and increased the time spent in the therapeutic zone ($p < 0.01$) (Sconce, 2007); Sconce *et al* demonstrated in their study that unstable patients had a low vitamin K intake [18]. Rombouts *et al.* demonstrated that the intake of 100 $\mu\text{g}/\text{d}$ of vitamin K for 6 months did not significantly increase the time spent in the therapeutic zone but did improve the chances of achieving maximum stability [20]. On the other hand, Franco V *et al.*, in a prospective randomized crossover study (n = 12), showed an association between an increase in vitamin K consumption and a decrease in INR ($p = 0.04$) and vice versa ($p = 0.005$) [21]. Rombouts *et al.* looked at patients with sub-therapeutic INR levels and showed that these under-dosed patients had more frequent recurrences of thromboembolic events [22]. Similarly, the same authors evaluated [17] the link between the strictness of the vitamin K-free diet and the frequency of episodes of sub-therapeutic INR. They were able to show that patients with a high daily intake of vitamin K-rich foods had a significantly lower risk of having their INR underdosed than patients with a "normal" intake of dietary vitamin K. The results of these studies clearly show that low daily intakes do not enable patients to receive effective treatment. All the patients treated with anti-vitamin K had very high energy intakes. This can be explained by the fact that the vegetables that patients should be eating are certainly being replaced by other, more energy-dense foods. In addition, vegetables are rich in fiber and therefore have a high satiating power. As a result, patients who do not eat vegetables will not feel full as soon as they do, which could lead them to consume large quantities of food. Furthermore, restricted consumption of green vegetables could contribute

to increasing the risks associated with a low intake of vitamin K, particularly with regard to bone and cardiovascular health [23], in addition to reducing the intake of other nutrients, including folates and carotenoids [1]. Anticoagulant therapy with warfarin has been associated with altered folate status [12] [24] [25].

6. Conclusion

At the end of this study, it emerged that patients undergoing anti-vitamin K treatment at the University Cardiology Clinic generally benefited from nutritional management based on the restriction of vitamin K-rich foods. This dietary restriction alters the dietary behavior of patients, who experience dietary “burn-out” sometime after the restriction has been complied with. Despite all the difficulties experienced by patients and the constraints associated with their treatment, the majority of these patients complied with the restriction, but only 2.5% - 5% had effective VKA treatment. Restricting vitamin K-rich foods does not therefore guarantee effective treatment. What’s more, this diet does not promote good nutrition for patients, exposing them instead to a high energy intake with a diet mainly geared towards carbohydrates and lipids, which can lead to weight gain: risk factors for cardiovascular disease. It would therefore be wise to review the diet of these patients in order to offer them a better lifestyle to optimize their treatment.

Conflicts of Interest

The authors declare no conflicts of interest regarding the publication of this paper.

References

- [1] Leblanc, C. (2015) Warfarin Anticoagulation Therapy: Influence of Dietary Vitamin K Intake. Thesis, Faculty of Medicine, Montréal.
- [2] Baker, J.W., Pierce, K.L. and Ryals, C.A. (2011) INR Goal Attainment and Oral Anticoagulation Knowledge of Patients Enrolled in an Anticoagulation Clinic in a Veterans Affairs Medical Center. *Journal of Managed Care Pharmacy*, **17**, 133-142. <https://doi.org/10.18553/jmcp.2011.17.2.133>
- [3] Jank, S., Bertsche, T., Herzog, W. and Haefeli, W.E. (2008) Patient Knowledge on Oral Anticoagulants: Results of a Questionnaire Survey in Germany and Comparison with the Literature. *International Journal of Clinical Pharmacology and Therapeutics*, **46**, 280-288. <https://doi.org/10.5414/CP46280>
- [4] Bellinge, J.W., Dalgaard, F., Murray, K., Connolly, E., Lauren, C., Lewis, C.P., *et al.* (2021) Vitamin K Intake and Atherosclerotic Cardiovascular Disease in the Danish Diet Cancer and Health Study. *Journal of the American Heart Association*, **10**, e020551. <https://doi.org/10.1161/JAHA.120.020551>
- [5] Hirsh, J. and Raschke, R. (2004) Heparin and Low-Molecular-Weight Heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest*, **126**, 188S-203S. https://doi.org/10.1378/chest.126.3_suppl.188S
- [6] Ansell, J., Hirsh, J., Poller, L., Bussey, H., Jacobson, A. and Hylek, E. (2004) The

- Pharmacology and Management of the Vitamin K Antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest*, **126**, 204S-233S. https://doi.org/10.1378/chest.126.3_suppl.204S
- [7] AFSSAPS (2002) Antidote au surdosage en antivitamine K: Indications du plasma frais congelé et des alternatives (vitamine K, concentré de complexe prothrombinique). In: *Transfusion de plasma frais congelé. Produits, Indications*, Agence Française de Sécurité Sanitaire des Produits de Santé, Saint-Denis, 18-19.
- [8] Baker, R.I., Coughlin, P.B., Gallus, A.S., Harper, P.L., Salem, H.H. and Wood, E.M. (2004) Warfarin Reversal: Consensus Guidelines, on Behalf of the Australasian Society of Thrombosis and Haemostasis. *The Medical Journal of Australia*, **181**, 492-497. <https://doi.org/10.5694/j.1326-5377.2004.tb06407.x>
- [9] Baglin, T.P., Keeling, D.M. and Watson, H.G. (2006) Guidelines on Oral Anticoagulation (Warfarin, Third Edition: 2005 Update). *British Journal of Haematology*, **132**, 277-285. <https://doi.org/10.1111/j.1365-2141.2005.05856.x>
- [10] Vigue, B., Ract, C., Tremey, B., Engrand, N., Leblanc, P.E., Decaux, A., *et al.* (2007) Ultra-Rapid Management of Oral Anticoagulant Therapy-Related Surgical Intracranial Hemorrhage. *Intensive Care Medicine*, **33**, 721-725. <https://doi.org/10.1007/s00134-007-0528-z>
- [11] Yasaka, M., Sakata, T., Minematsu, K. and Naritomi, H. (2002) Correction of INR by Prothrombin Complex Concentrate and Vitamin K in Patients with Warfarin Related Hemorrhagic Complication. *Thrombosis Research*, **108**, 25-30. [https://doi.org/10.1016/S0049-3848\(02\)00402-4](https://doi.org/10.1016/S0049-3848(02)00402-4)
- [12] Sobczyk, ska-Malefora, A., Harrington, D.J., Lomer, M.C., Pettitt, C., Hamilton, S., Rangarajan, S. and Shearer, M.J. (2009) Erythrocyte Folate and 5-Methyltetrahydrofolate Levels Decline during 6 Months of Oral Anticoagulation with Warfarin. *Blood Coagulation & Fibrinolysis*, **20**, 297-302. <https://doi.org/10.1097/MBC.0b013e32832aa6a1>
- [13] Kurnik, D., Loebstein, R., Rabinovitz, H., Austerweil, N., Halkin, H. and Almog, S. (2004) Over-the-Counter Vitamin K1-Containing Multivitamin Supplements Disrupt Warfarin Anticoagulation in Vitamin K1-Depleted Patients. A Prospective, Controlled Trial. *Thrombosis and Haemostasis*, **92**, 1018-1024. <https://doi.org/10.1160/TH04-06-0346>
- [14] Li, R.C., Finkelman, B.S., Chen, J., Booth, S.L., Bershaw, L., Brensinger, C. and Kimmel, S.E. (2013) Dietary Vitamin K Intake and Anticoagulation Control during the Initiation Phase of Warfarin Therapy: A Prospective Cohort Study. *Thrombosis and Haemostasis*, **110**, 195-196. <https://doi.org/10.1160/TH13-02-0111>
- [15] Leblanc, C., Presse, N., Lalonde, G., Dumas, S. and Ferland, G. (2014) Higher Vitamin K Intake Is Associated with Better INR Control and a Decreased Need for INR Tests in Long-Term Warfarin Therapy. *Thrombosis Research*, **134**, 210-212. <https://doi.org/10.1016/j.thromres.2014.04.024>
- [16] Baker, W.L., Cios, D.A., Sander, S.D. and Coleman, C.I. (2009) Meta-Analysis to Assess the Quality of Warfarin Control in Atrial Fibrillation Patients in the United States. *Journal of Managed Care Pharmacy*, **15**, 244-252. <https://doi.org/10.18553/jmcp.2009.15.3.244>
- [17] Rombouts, E.K., Rosendaal, F.R. and van der Meer, F.J. (2010) Influence of Dietary Vitamin K Intake on Subtherapeutic Oral Anticoagulant Therapy. *British Journal of Haematology*, **149**, 598-605. <https://doi.org/10.1111/j.1365-2141.2010.08108.x>
- [18] Scone, E., Khan, T., Mason, J., Noble, F., Whyne, H. and Kamali, F. (2005) Patients with Unstable Control Have a Poorer Dietary Intake of Vitamin k Compared to Pa-

- tients with Stable Control of Anticoagulation. *Thrombosis and Haemostasis*, **93**, 872-875. <https://doi.org/10.1160/TH04-12-0773>
- [19] Schurgers, L.J., Shearer, M.J., Hamulyak, K., *et al.* (2004) Effect of Vitamin K Intake on the Stability of Oral Anticoagulant Treatment: Dose-Response Relationships in Healthy Subjects. *Blood*, **104**, 2682-2689. <https://doi.org/10.1182/blood-2004-04-1525>
- [20] Rombouts, E.K., Rosendaal, F.R. and Van Der Meer, F.J. (2007) Daily Vitamin K Supplementation Improves Anticoagulant Stability. *Journal of Thrombosis and Haemostasis*, **5**, 2043-2048. <https://doi.org/10.1111/j.1538-7836.2007.02715.x>
- [21] Franco, V., Polanczyk, C.A., Clausell, N., *et al.* (2004) Role of Dietary Vitamin K Intake in Chronic Oral Anticoagulation: Prospective Evidence from Observational and Randomized Protocols. *The American Journal of Medicine*, **116**, 651-656. <https://doi.org/10.1016/j.amjmed.2003.12.036>
- [22] Rombouts, E.K., Rosendaal, F.R. and van der Meer, F.J. (2009) Subtherapeutic Oral Anticoagulant Therapy: Frequency and Risk Factors. *Thrombosis and Haemostasis*, **101**, 552-556. <https://doi.org/10.1160/TH08-09-0626>
- [23] Ferland, G. (2012) Vitamin K. In Erdman, J.W., Macdonald, I.A. and Zeisel, S.H., Eds., *Present Knowledge in Nutrition*, 10th Edition, Wiley-Blackwell, Ames, 230-247.
- [24] Murúa, A., Quintana, I., Galarza, C., *et al.* (2001) Unsuspected Hyperhomocysteinemia in Chronically Anticoagulated Patients. *Blood Coagulation & Fibrinolysis*, **12**, 79-80. <https://doi.org/10.1097/00001721-200101000-00012>
- [25] Sobczynska-Malefora, A., Harrington, D.J., Rangarajan, S., *et al.* (2003) Hyperhomocysteinemia and B-Vitamin Status after Discontinuation of Oral Anticoagulation Therapy in Patients with a History of Venous Thromboembolism. *Clinical Chemistry and Laboratory Medicine*, **41**, 1493-1497. <https://doi.org/10.1515/CCLM.2003.229>